CVE-2021-40407
Reolink RLC-410W IP Camera OS Command Injection Vulnerability
- Critical 9.1
- Exploited: added to CISA KEV 18 Dec 2024
Description
An OS command injection vulnerability exists in the device network settings functionality of reolink RLC-410W v3.0.0.136_20121102. At [1] or [2], based on DDNS type, the ddns->domain variable, that has the value of the domain parameter provided through the SetDdns API, is not validated properly. This would lead to an OS command injection. An attacker can send an HTTP request to trigger this vulnerability.
Key facts
- Published
- 28 Jan 2022
- Last changed
- 21 Oct 2025
- Assigned by
- talos
- KEV added
- 18 Dec 2024
- KEV fix due
- 8 Jan 2025
- EPSS
- 47.635% likely to be exploited in the next 30 days, higher than 98.868% of CVEs (scores for 15 Nov 2026)
- SSVC (CISA)
- Exploitation: active; Automatable: no; Technical impact: total
Severity scores
Each score is shown as its source gave it. They are not averaged or merged.
- 9.1CVSS 3.0, Criticalfrom the CNA (talos)
CVSS:3.0/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H
What to do
- The impacted product could be end-of-life (EoL) and/or end-of-service (EoS). Users should discontinue product utilization if a current mitigation is unavailable.CISA KEV required action
Historical context and remediation
This reference retains the original CVE publication date. A recent record update does not mean a new attack occurred.
No separately sourced impact summary is available on this page yet. Consult the description, version data and dated exploitation evidence.
Version statuses below come from the CNA. An “unaffected” version is not necessarily a currently supported release or proof of a patch date. EPSS is a dated risk estimate, not a count of historical attacks.
Affected products
| Vendor | Product | Versions |
|---|---|---|
| n/a | n/a |
|
Timeline
- 28 Jan 2022 Published
- 18 Dec 2024 CVE-2021-40407 added to CISA KEV
- 18 Dec 2024 Added to the CISA KEV catalogue
Weakness
Practice this bug class
HackZoneLabs has a hands-on lab on OS command injection (CWE-78).